[1]菲尔凯提·玉山江李昊穆叶赛·尼加提.射血分数保留性心力衰竭合并糖尿病的研究进展[J].心血管病学进展,2020,(4):373-376.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
　FEIERKAITI·Yushanjiang,LIHao,MUYESAI.Nijiati.Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(4):373-376.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
点击复制

射血分数保留性心力衰竭合并糖尿病的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年4期
页码:
373-376
栏目:
综述
出版日期:
2020-04-25

文章信息/Info

Title:
Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus
作者:
菲尔凯提·玉山江1李昊1穆叶赛·尼加提2
(1.新疆维吾尔自治区人民医院心内科,新疆 乌鲁木齐 830000;2.新疆维吾尔自治区人民医院急救中心,新疆 乌鲁木齐 830000)
Author(s):
FEIERKAITI·Yushanjiang1;  LIHao1;  MUYESAI.Nijiati2
 (1.Department of Cardiology,Xinjiang Uygur Autonomous Region People’s Hospital,Wulumuqi 830000,Xinjiang,China; 2.Department of emergency center,Xinjiang Uygur Autonomous Region People’s Hospital,Wulumuqi 830000,Xinjiang,China)
关键词:
射血分数保留性心力衰竭; 心力衰竭; 糖尿病
Keywords:
Ejection fraction preserves heart failure; Heart failure; Diabetes mellitus
DOI:
10.16806/j.cnki.issn.1004-3934.2020.04.011
摘要:
心力衰竭是一种心脏结构或功能异常所致的临床综合征，据推测目前中国心血管病患者人数为2.9亿，其中心力衰竭占据450万。依据左心室射血分数，心力衰竭又分为射血分数降低性心力衰竭（HFrEF）和射血分数保留性心力衰竭（HFpEF）。近年来，HFpEF的发病率明显较HFrEF增加且已成为研究的热点。高血压、糖尿病和冠心病是常见能导致心力衰竭的基础疾病，其中糖尿病是最常见合并症之一。在美国，糖尿病在HFpEF中的患病率约为45％，但人们对这一人群的特征和结果了解甚少，在中国更是这样。现总结几项HFpEF治疗临床试验的数据，这些数据都表明糖尿病与HFpEF的发病率和长期死亡率增加有关，并讨论了HFpEF和糖尿病中的几种常见病理机制，包括钠潴留、代谢紊乱、骨骼肌功能受损和潜在的治疗靶点。 随着对合并HFpEF和糖尿病的理解的增加，希望能为临床医生更好地提供有效的治疗方法。
Abstract:
Heart failure is a clinical syndrome caused by abnormal heart structure or function.It is estimated that there are 290 million patients with cardiovascular disease in China ,and the number of patients with central failure is 4.5 million. Based on the left ventricular ejection fraction, heart failure is divided into heart failure with reduced ejection fraction(HFrEF) and heart failure with preserved ejection fraction(HFpEF).In recent years, the incidence of HFpEF has increased significantly compared with HFrEF and has become a research hotspot. The most common underlying diseases that cause heart failure are high blood pressure,diabetes mellitus(DM),and coronary heart disease,of which DM is one of the most common comorbidities. In the United States ,the prevalence of DM in HFpEF is about 45% ,but little is known about the characteristics and outcomes of this population,especially in our country.In this review,several data from clinical trials of HFpEF therapy are summarized. These data suggest that DM is associated with increased morbidity and long-term mortality of HFpEF ,and several common pathological mechanisms in HFpEF and DM are discussed,including sodium retention, metabolic disorders,impaired skeletal muscle function and potential therapeutic targets.With the increased understanding of HFpEF and DM,it is hoped to provide effective treatment methods for clinicians.

参考文献/References:


[1] 刘长清,樊光辉. 射血分数保留的心力衰竭合并2型糖尿病患者的临床特征分析[J]. 中国心血管杂志,2018,23(3):251-255.

[2] International Diabetes Federation. IDF Diabetes Atlas. 8th ed. 2017.

[3] Sandesara PB,O’Neal WT,Kelli HM et al. The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction[J]. Diabetes Care,2018,41(1):150-155.

[4] Echouffo-Tcheugui JB,Xu H,DeVore AD,et al.Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure:findings from Get With The Guidelines-Heart Failure registry[J]. Am Heart J,2016,182:9-20.

[5] Fonarow GC,Stough WG,Abraham WT,et al. Characteristics,treatments,and outcomes of patients with preserved systolic function hospitalized for heart failure:a report from the OPTIMIZE-HF registry[J]. J Am Coll Cardiol,2007,50(8):768-777.

[6] Cheng RK,Cox M,Neely ML,et al. Outcomes inpatients with heart failure with preserved,borderline,and reduced ejection fraction in the Medicare population[J]. Am Heart J,2014,168(5):721-730.

[7] Dhingra A,Garg A,Kaur S,et al. Epidemiology of heart failure with preserved ejection fraction[J]. Curr Heart Fail Rep,2014,11(4):354-365.

[8] Parikh KS,Sharma K,Fiuzat M,et al. Heart failure with preserved ejection fraction expert panel report:current controversies and implications for clinical trials[J]. JACC Heart Fail ,2018,6(8):619-632.

[9] De Groote P,Lamblin N,Mouquet F,et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure[J]. Eur Heart J,2004,25(8):656-662.

[10] MacDonald MR,Petrie MC,Varyani F,et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure:an analysis of the Candesartan in Heart failure:Assessment of Reduction in Mortality and morbidity (CHARM) programme[J]. Eur Heart J,2008,29(11):1377-1385.

[11] Lund LH,Claggett B,Liu J,et al. Heart failure with mid-range ejection fraction in CHARM:characteristics,outcomes and effect of candesartan across the entire ejection fraction spectrum[J]. Eur J Heart Fail,2018,20(8):1230-1239.

[12] Aguilar D,Deswal A,Ramasubbu K,et al. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus[J]. Am J Cardiol,2010,10(3)5:373-377.

[13] Lindman BR,Davila-Roman VG,Mann DL,et al. Cardiovascular phenotype in HFpEF patients with or without diabetes:a RELAX trial ancillary study[J]. J Am Coll Cardiol,2014,64(6):541-549.

[14] Kristensen SL,Mogensen UM,Jhund PS,et al. Clinical and echocardiographic character-istics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction:a report from the I-Preserve trial (Irbesartan in Heart Failure WithPreserved Ejection Fraction)[J]. Circulation ,2017,135(8):724-735.

[15] Smaha LA,American Heart Association. The American Heart Association Get With The Guidelines program[J]. Am Heart J ,2004,148(5 Suppl):S46-S48.

[16] Steinberg BA,Zhao X,Heidenreich PA,et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction:prevalence,therapies,and outcomes[J]. Circulation 2012 ,126(1):65-75.

[17] Heerspink HJ,Perkins BA,Fitchett DH,Husain M,Cherney DZ. Sodium glucose cotrans-porter 2 inhibitors in the treatment of diabetes mellitus:cardiovascular and kidney effects,potential mechanisms,and clinical applications[J]. Circulation ,2016,134(10):752-772.

[18] Zinman B,Wanner C,Lachin JM,et al. Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes[J]. N Engl J Med , 2015 ,373(22):2117-2128.

[19] Butler J,Hamo CE,Filippatos G,et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors[J]. Eur J Heart Fail ,2017,19(11):1390-1400.

[20] Patorno E,Pawar A,Franklin JM,et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care[J]. Circulation ,2019,139(25):2822-2830.

[21] von Scholten BJ,Persson F,Rosenlund S,et al. Effects of liraglutide on cardiovascular risk bio-markers in patients with type 2 diabetes and albuminuria:a sub-analysis of a randomized,placebo-controlled,double-blind,crossover trial[J]. Diabetes Obes Metab,2017,19(6):901-905.

[22] Jojima T,Uchida K,Akimoto K,et al. Liraglutide,a GLP-1 receptor agonist,inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation,and delays atherosclerosis in ApoE deficient mice[J]. Atherosclerosis,2017,261:44-51.

相似文献/References:

[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
　DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(4):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
　LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(4):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
　ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(4):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
　LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
　KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
　SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(4):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
　XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(4):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
　GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(4):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
　HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(4):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
　WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(4):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[11]石玉姣 熊双 刘春秋 杨晨光 董国菊 刘剑刚.射血分数保留性心力衰竭潜在的分子机制及治疗靶点[J].心血管病学进展,2022,(5):423.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.010]
　SHI Yujiao,XIONG Shuang,LIU Chunqiu,et al.Potential Molecular Mechanisms and Therapeutic Target in Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(4):423.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.010]
[12]贾晓艳 安晋阳 彭可玲 刘永铭.可溶性鸟苷酸环化酶激动剂治疗射血分数保留性心力衰竭的研究进展[J].心血管病学进展,2022,(2):141.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.012]
　JIA Xiaoyan,AN Jinyang,PENG Keling,et al.Soluble Guanylate Cyclase Stimulators in the Treatment of Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(4):141.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.012]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金项目（81760068）
通信作者：穆叶赛·尼加提，E-mail：muyassar11@aliyun.com
收稿时间：2019-09-18
更新日期/Last Update: 2020-07-28